Avadel dips after disappointing 2025 revenue outlook

Avadel Pharmaceuticals

10/01/2025 13:25

** Shares of Avadel Pharmaceuticals  AVDL.O  fall ~25% to
$8.01 premarket  
    ** Late on Wednesday AVDL forecast 2025 rev in the range of
$240 mln to $260 mln 
    ** Analysts on average estimate total revenue of about
$267.6 mln -LSEG data   
    ** At least two brokerages cut PT on AVDL following the
disappointing 2025 outlook
    ** H.C.Wainwright analysts expect a slower revenue ramp up
for its sleep disorder drug Lumryz   
    ** Up to last close, stock down ~32% over the past 12 months

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))